Gain Therapeutics’ (GANX) Buy Rating Reaffirmed at Roth Mkm

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reissued by equities research analysts at Roth Mkm in a research note issued on Tuesday,Benzinga reports. They currently have a $7.00 price target on the stock. Roth Mkm’s target price would indicate a potential upside of 336.27% from the stock’s previous close.

Several other research analysts have also recently issued reports on the company. Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research note on Monday, November 25th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gain Therapeutics presently has a consensus rating of “Buy” and an average target price of $7.25.

Gain Therapeutics Stock Performance

NASDAQ GANX traded up $0.03 on Tuesday, hitting $1.60. The stock had a trading volume of 99,210 shares, compared to its average volume of 262,513. The company’s 50-day moving average is $2.03 and its two-hundred day moving average is $1.61. The stock has a market cap of $42.56 million, a price-to-earnings ratio of -1.46 and a beta of 0.21. The company has a quick ratio of 2.99, a current ratio of 2.99 and a debt-to-equity ratio of 0.04. Gain Therapeutics has a one year low of $0.89 and a one year high of $5.33.

Institutional Investors Weigh In On Gain Therapeutics

Large investors have recently bought and sold shares of the business. Warberg Asset Management LLC acquired a new stake in shares of Gain Therapeutics in the second quarter worth $66,000. Renaissance Technologies LLC raised its holdings in shares of Gain Therapeutics by 154.2% in the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock valued at $152,000 after buying an additional 72,000 shares during the last quarter. Geode Capital Management LLC grew its holdings in Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after acquiring an additional 88,236 shares during the last quarter. Finally, Hohimer Wealth Management LLC bought a new position in shares of Gain Therapeutics in the second quarter worth about $422,000. 11.97% of the stock is currently owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.